Cannabis Law Report

FEBRUARY 2, 2022

– Flora’s research division, Flora Pharma, files USPTO provisional patent application on a cannabinoid-based formula. – Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA).

Cannabinoids 52

Cannabinoids Clinical Trials Events Cultivation 52

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events.

Safety 52

Safety Cannabinoids Events Data 52

Veriheal

MAY 26, 2022

Dedicated to “redefining what’s possible,” the 501(c)(3) organization has provided 1:1 support and resources to over 69,000 clients as they navigated plant-powered cannabinoid therapy. Of course, legalization and education efforts can only go so far without data, and that’s where RoC’s research initiatives come into play.

Advocacy 96

Advocacy Patients Clinical Trials Education 96

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. (“Shanti”), and all its assets focused on psychedelic MDMA-based drug development. from 2020 to 2030 and generate revenue of $151.7

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

NOVEMBER 22, 2021

Emyria was listed on the ASX last year, just before Australia was plunged into the global COVID-19 pandemic, and has been progressing with trials of a synthetic cannabinoid targeting mental health which it hopes to have registered domestically and in the American market.

Clinical Trials 52

Clinical Trials Treatment Medicine Cannabinoids 52

Cannabis Law Report

SEPTEMBER 14, 2021

A lack of consumer trust, transparency and scientific rigor has hampered the CBD and cannabinoid industry from reaching its growth potential for far too long”.

Extraction 52

Extraction Research and Development Clinical Trials CBD 52

Cannabis Law Report

MARCH 22, 2020

A data firm is warning those infected with the novel coronoavirus to avoid consuming products that contain tetrahydrocannabinol (THC), the main psychoactive component of cannabis. Data CEO Julie Armstrong said her company knows the COVID-19 affects the population in a similar way to influenza.

THC 59

THC Clinical Trials Data Consumption 59

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. However, a result can be statistically significant but not clinically significant–meaning that even though a study may detect a difference on paper, it may make no tangible difference in real-world application.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Veriheal

AUGUST 31, 2020

Data shows that Hispanic Americans are more interested in using cannabis and CBD for wellness than other groups and “is believed to be in part due to the connections between the Hispanic community and nature.” Essay: “Crowdsourcing User Experience Data for a Targeted Medical Cannabis Journey with Cannamunity” .

Research and Development 117

Research and Development Education Agriculture Patients 117

The Herb Collective

JUNE 3, 2018

Slows the Progression of Cancer Cells While scientists are still researching CBD oil’s ability to delay the onset of Cancer, clinical trials and American Cancer Society efficacy data suggest that CBD oil combats two conditions associated with cancer cells – oxidative stress and inflammation. There is even CBD Oil for your pets

Oil 56

Oil CBD Blood Pressure Chronic Pain 56

Puff Puff Post

NOVEMBER 5, 2019

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Cannabis Law Report

JUNE 10, 2021

Studies of crash or driving data suggest that, although permissive marijuana policies are associated with higher prevalence of tetrahydrocannabinol (THC) presence among drivers [ 1 , 2 ], there is mixed evidence that these policies are associated with motor vehicle crashes [ 3 , 4 , 5 , 6 , 7 , 8 , 9 ]. never vs. at least once). (2)

Policy 59

Policy Safety Marijuana Data 59

The Cannigma

FEBRUARY 11, 2021

Listen & Subscribe: When Mara Gordon started using medical cannabis there wasn’t any lab testing — or any way to know how much of each cannabinoid or terpene was in a given strain. One of the things she does is collect and analyze data about cannabis products and how patients with different medical conditions respond to them.

Wellness and Beauty 125

Wellness and Beauty Data Patients Medicine 125

Puff Puff Post

NOVEMBER 5, 2019

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

The Joint Blog

FEBRUARY 18, 2020

According to NORML, they reported that the use of medical cannabis, and in particular products dominant in the cannabinoid CBN (cannabinol), was associated with medication-sparing effects. The study is titled Cannabinoid and terpenoid doses are associated with adult ADHD status of medical cannabis patients.

Clinical Trials 45

Clinical Trials Terpenes Data Cannabinoids 45

CannaMD

MARCH 8, 2020

Few randomized clinical trials have been conducted or are planned to explore the effects of marijuana on cardiovascular risk. Screening and testing for use of marijuana are encouraged in clinical settings, especially in the care of young patients presenting with cardiovascular disease. More research is needed.

Patients 79

Patients Marijuana Research and Development Clinical Trials 79

CannaMD

OCTOBER 7, 2019

In 2011, researchers published cross-sectional data from two population-based surveys including over 50,000 respondents. While scientists are still searching for a definitive explanation, researchers with Cannabis and Cannabinoid Research have an interesting theory. Believe it or not, science says: YES. And the coolest part?

Marijuana 105

Marijuana Cannabinoids Patients Conditions 105

Cannabis Law Report

NOVEMBER 7, 2019

Cannatrek will thoroughly control, analyse and optimise every step of its production to ensure the quality of the finished product using climatic and cultivation data combined with patient data, gathered in house. Cannatrek is actively working on clinical trial protocols with a dedicated focus on mental health.

Medicine 40

Medicine Patients Research and Development Clinical Trials 40

Cannabis Law Report

NOVEMBER 24, 2021

At the same time, the outlook on cannabis research data is largely positive. The recreational use of cannabis is well known and attributed to its power as a psychotropic plant, specifically due to the cannabinoid tetrahydrocannabinol (THC). Data collection. This offers a more denotative approach to complement the data.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

OCTOBER 29, 2019

The PK data on cats shows there are differences in absorption between cats and dogs and that dosing may be different between these two species and that our chew form is likely to be more absorbable than oils in general. This data gives us confidence in the use of both the chew and the oils as effective means for delivering CBD to your pet.”.

Safety 45

Safety CBD Clinical Trials Oil 45

Cannabis Law Report

DECEMBER 7, 2021

“Despite the massive and growing market size, there is still scant data on the effectiveness of over-the-counter cannabinoid products due to the cost, speed and scale limitations of the current approach to scientific research,” said Jeff Chen, MD/MBA, Co-founder and CEO of Radicle Science. in less than four days. About Radicle Science.

Clinical Trials 52

Clinical Trials CBD Data Sleep 52

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Rick Doblin, Ph.D, in/rickdoblin/ [link]. in/ingmargorman/ [link]. in/gpechenik/ [link]. James Keim. Mimosa Therapeutics. in/judyblumstock.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51